Navigation

Hepatitis C - peginterferon alfa and ribavirin

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part-review of TA75 and TA106)

Status: History
Expected date of issue: September 2010
Process: MTA
Topic area:
 

NICE project team

Executive Lead: Gillian Leng
Technical Lead: Fiona Rinaldi
Project manager: Jeremy Powell
Assessment Group / Evidence Review Group: Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: 15 April 2009
Information meeting with consultees: 30 June 2009
Closing date for invited submissions / evidence submission: 20 August 2009
Final scope published: May 2009
1st appraisal committee meeting: 06 April 2010
2nd appraisal committee meeting: 01 July 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Roche Products ( peginterferon alfa-2a, ribavirin)
  • Schering-Plough (now Merck Sharpe & Dohme) (peginterferon alfa-2b, ribavirin)

Patient/carer Groups

  • British Liver Trust
  • Haemophilia Alliance
  • Haemophilia Society
  • Hepatitis C Trust
  • South Asian Health Foundation

Professional groups

  • Association of Medical Microbiologists
  • British Association for the Study of the Liver
  • British Association for the Study of the Liver Nurses Forum
  • British Infection Society
  • British Society of Gastroenterology
  • British Viral Hepatitis Group
  • Royal College of Nursing
  • Royal College of Pathologist
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • None

Relevant research groups

  • Foundation for Liver Research
  • MRC Clinical Trials Unit

Assessment team

  • Southampton Health Technology Assessment Centre, University of Southampton

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Key documents

This page was last updated: 20 April 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.